Rocket Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Rocket Pharmaceuticals ont diminué à un taux annuel moyen de -22.4%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 19.3% par an.

Informations clés

-22.4%

Taux de croissance des bénéfices

-10.8%

Taux de croissance du BPA

Biotechs Croissance de l'industrie	17.0%
Taux de croissance des recettes	n/a
Rendement des fonds propres	-78.3%
Marge nette	n/a
Dernière mise à jour des bénéfices	30 Sep 2024

Mises à jour récentes des performances passées

Pas de mise à jour

Recent updates

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Rocket earns Evercore nod after positive data for rare genetic disease

Dec 17

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

Dec 09

Ventilation des recettes et des dépenses

Comment Rocket Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

NasdaqGM:RCKT Recettes, dépenses et bénéfices (USD Millions )
Date	Les revenus	Dépenses G+A	Dépenses de R&D
30 Sep 24	-258	98	176
30 Jun 24	-253	90	180
31 Mar 24	-249	80	185
31 Dec 23	-246	73	186
30 Sep 23	-253	68	194
30 Jun 23	-249	64	191
31 Mar 23	-237	60	181
31 Dec 22	-222	56	165
30 Sep 22	-199	51	148
30 Jun 22	-192	46	144
31 Mar 22	-172	43	127
31 Dec 21	-169	42	124
30 Sep 21	-186	40	142
30 Jun 21	-165	35	124
31 Mar 21	-155	33	116
31 Dec 20	-140	29	105
30 Sep 20	-99	25	70
30 Jun 20	-89	23	63
31 Mar 20	-82	21	60
31 Dec 19	-77	18	58
30 Sep 19	-85	15	67
30 Jun 19	-82	13	66
31 Mar 19	-79	8	62
31 Dec 18	-75	13	53
30 Sep 18	-54	11	34
30 Jun 18	-44	11	26
31 Mar 18	-32	13	18
31 Dec 17	-20	5	15
30 Sep 17	-16	4	12
30 Jun 17	-11	2	9
31 Mar 17	-9	2	7
31 Dec 16	-8	2	6

Des revenus de qualité: RCKT n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: RCKT n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: RCKT n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 22.4% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de RCKT au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: RCKT n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 16.6% ).

Rendement des fonds propres

ROE élevé: RCKT a un retour sur capitaux propres négatif ( -78.26% ), car il n'est actuellement pas rentable.

Rocket Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Recent updates

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Consensus revenue estimates fall by 11%

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$309k worth of stock

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Consensus revenue estimates decrease by 57%, EPS upgraded

VP, Senior Controller notifies of intention to sell stock

Rocket Pharmaceuticals' Promising Path In Gene Therapy

No longer forecast to breakeven

New minor risk - Insider selling

CEO & Director recently sold US$605k worth of stock

CEO & Director notifies of intention to sell stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold US$88k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 95%

CEO & Director notifies of intention to sell stock

Insider recently sold US$68k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Now 23% undervalued

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Price target decreased to US$53.18

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Rocket Pharma: Poised For Growth In The Rare Disease Space

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Price target decreased to US$58.50

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

Price target decreased to US$63.56

Consensus forecasts updated

CEO & Director recently bought US$382k worth of stock

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24Th Annual Meeting of the American Society of Gene and Cell Therapy

CEO, President & Director exercised options and sold US$3.2m worth of stock

COO, Executive VP & Head of Development exercised options to buy US$4.4m worth of stock.

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

Insider exercised options to buy US$14m worth of stock.